Obio Technology (Shanghai) 과거 수익 실적
과거 기준 확인 0/6
Obio Technology (Shanghai)'s earnings have been declining at an average annual rate of -68.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 10.1% per year.
주요 정보
-68.2%
수익 성장률
-61.8%
EPS 성장률
| Life Sciences 산업 성장 | 26.8% |
| 매출 성장률 | 10.1% |
| 자기자본 수익률 | -13.2% |
| 순이익 | -98.0% |
| 다음 실적 업데이트 | 13 Nov 2024 |
최근 과거 실적 업데이트
Recent updates
Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Looks Just Right With A 27% Price Jump
Oct 01
Some Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 21Subdued Growth No Barrier To Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) With Shares Advancing 30%
Mar 06수익 및 비용 분석
Obio Technology (Shanghai) 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 252 | -247 | 127 | 50 |
| 30 Jun 24 | 234 | -196 | 127 | 54 |
| 31 Mar 24 | 234 | -138 | 116 | 53 |
| 31 Dec 23 | 205 | -128 | 106 | 51 |
| 30 Sep 23 | 213 | -66 | 100 | 51 |
| 30 Jun 23 | 240 | -26 | 92 | 47 |
| 31 Mar 23 | 249 | -5 | 90 | 39 |
| 31 Dec 22 | 291 | 39 | 89 | 35 |
| 30 Sep 22 | 306 | 59 | 85 | 32 |
| 30 Jun 22 | 291 | 59 | 82 | 29 |
| 31 Mar 22 | 281 | 57 | 79 | 28 |
| 31 Dec 21 | 255 | 54 | 69 | 24 |
| 30 Sep 21 | 231 | 52 | 60 | 18 |
| 31 Dec 20 | 143 | 94 | 52 | 22 |
| 31 Dec 19 | 63 | -37 | 47 | 24 |
| 30 Jun 19 | 52 | -38 | 51 | 22 |
| 31 Mar 19 | 47 | -33 | 44 | 21 |
| 31 Dec 18 | 44 | -32 | 37 | 20 |
| 30 Sep 18 | 39 | -23 | 31 | 16 |
| 30 Jun 18 | 35 | -18 | 25 | 13 |
| 31 Mar 18 | 31 | -19 | 24 | 12 |
| 31 Dec 17 | 28 | -20 | 23 | 11 |
| 30 Sep 17 | 25 | -14 | 23 | 8 |
| 30 Jun 17 | 23 | -9 | 23 | 4 |
| 31 Mar 17 | 21 | -8 | 25 | 2 |
| 31 Dec 16 | 20 | -7 | 26 | 0 |
| 31 Dec 15 | 14 | -1 | 12 | 0 |
| 31 Dec 14 | 8 | -4 | 9 | 0 |
양질의 수익: 688238 is currently unprofitable.
이익 마진 증가: 688238 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 688238 is unprofitable, and losses have increased over the past 5 years at a rate of 68.2% per year.
성장 가속화: Unable to compare 688238's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: 688238 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.4%).
자기자본 수익률
높은 ROE: 688238 has a negative Return on Equity (-13.23%), as it is currently unprofitable.